On April 28, 2026, the newly reconstituted Interagency Autism Coordinating Committee (IACC), remade by HHS Secretary Robert F. Kennedy Jr. in January, issued its first set of proposals focusing on "profound autism" and the systematic treatment of co-occurring medical conditions in autistic individuals. The committee recommended that federal agencies adopt the term "profound autism" for those with the highest support needs, including minimal verbal ability and significant intellectual disability, while urging doctors to treat caregiver observations as medically relevant rather than anecdotal. It highlighted the need for better recognition of seizures, sleep disturbances, gastrointestinal issues, allergic diseases, and developmental regression—conditions frequently overlooked or dismissed as mere behavioral aspects of autism. Chair Dr. Sylvia Fogel, a Harvard psychiatry instructor with a profoundly autistic son, emphasized that undiagnosed psychiatric and pain-related conditions in this population are unacceptable and correctable. These proposals address what the committee described as a "translational gap" where clinical evidence exists but is not consistently applied, resulting in fragmented care and preventable harm. While mainstream coverage frames the overhaul as controversial due to the inclusion of members skeptical of official vaccine-autism dismissals, a deeper pattern emerges: for decades, federal autism policy has prioritized genetic research and behavioral interventions while sidelining environmental factors and comorbidities. Kennedy's remaking of the IACC—replacing prior members with those open to investigating triggers beyond genetics—mirrors historical medical establishment resistance seen in delayed acknowledgments of tobacco risks, opioid overprescription, and other environmental contributors to chronic disease. By directing agencies like HRSA and CMS to train clinicians on these issues and pursue evaluation when regression or allergic signals appear, the committee challenges the paradigm that has long treated autism as primarily idiopathic or genetic, potentially reopening inquiry into vaccine schedules, heavy metals, pesticides, and immune dysregulation that independent researchers have flagged but institutions have marginalized. Critics quickly formed an Independent Autism Coordinating Committee to counter what they call an ideological shift, yet the official body's focus on profound autism and medical integration aligns with growing parental reports and clinical observations long present in the literature but under-integrated into policy. This move could mark a pivotal reconnection of autism research with environmental medicine, exposing how institutional inertia and liability concerns have perpetuated gaps at the expense of affected families. Real-world impact may include reformed diagnostic protocols, increased funding for comorbidity research, and pressure on the broader medical system to confront overlooked contributors rather than default to behavioral explanations.